Purpose
To determine the safety and efficacy of a urokinase-type plasminogen activator, saruplase, in comparison to streptokinase, for
the treatment of patients with AMI
References
Tebbe U, et al & Mlczoch J, for the Comparison Trial of Saruplase and Streptokinase (COMPASS) Investigators: Randomized,
double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS
equivalence trial. J Am Coll Cardiol 1998, 31:487-493. |
Farmacêutica